Levofloxacin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levofloxacin
- Molecular weight
- 740.76
- Structure (SMILES)
- C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.O
- evoxil
- Evoxil
- iquix
- Iquix
- levaquin
- Levaquin
- levofloxacin
- Levofloxacin
- oftaquix
- Oftaquix
- quinsair
- Quinsair
- quixin
- Quixin
- tavanic
- Tavanic
- (-)-(S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, HEMIHYDRATE
- 7h pyrido 1 2 3 de 1 4 benzoxazine 6 carboxylic acid 9 fluoro 2 3 dihydro 3 methyl 10 4 methyl 1 piperazinyl 7 oxo hydrate 2 1 s
- 7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-HYDRATE (2:1), (S)-
- cravit
- Cravit
- dr 3355
- DR-3355
- l ofloxacin
- L-ofloxacin
- levofloxacin
- Levofloxacin
- Levofloxacin (as hemihydrate)
- LEVOFLOXACIN [MART.]
- LEVOFLOXACIN [ORANGE BOOK]
- LEVOFLOXACIN [USAN]
- LEVOFLOXACIN [USP MONOGRAPH]
- LEVOFLOXACIN [USP-RS]
- LEVOFLOXACIN [VANDF]
- levofloxacin 0 5 eye drops solution oftaquix
- levofloxacin 0 5 ophthalmic solution cravit
- Levofloxacin 0.5% eye drops solution (Oftaquix®)
- Levofloxacin 0.5% ophthalmic solution (Cravit)
- levofloxacin as hemihydrate
- levofloxacin hemihydrate
- Levofloxacin hemihydrate
And 29 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL5315124
- InChIKey
- SUIQUYDRLGGZOL-RCWTXCDDSA-N
- PubChem compound IDs
- 3033924
- RxNorm IDs (RxCUI)
- 82122
- FDA ingredient codes (UNII)
- 6GNT3Y5LMF
- J01MA12
- S01AE05
Sources for recorded values
- 100986-85-4
- 138199-71-0
- Applicant
- JANSSEN PHARMS
- Approval date
- 20 Dec 1996
- Application number
- NDA020634
- Status
- Authorised
- Status date
- 25 Mar 2015
- Authorisation date
- 25 Mar 2015
- Approved indications
- Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Product number
- EMEA/H/C/002789
- Authorisation holder
- Chiesi Farmaceutici S.p.A
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Cystic Fibrosis
- Respiratory Tract Infections
European medicines record
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- levofloxacin
- Type
- Synthetic organic
- Drug name stem
- -oxacin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Mechanism
- DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- DNA gyrase
- Protein identifier
- P0A4L9
- Mechanism
- DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- DNA gyrase
- Protein identifier
- P72524
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Protein identifier
- P72525
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Protein identifier
- Q59961
- Mechanism
- DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- DNA gyrase
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Action type
- Inhibitor
- Gene symbol
- gyrB|gyrA
- Protein identifier
- P0A4L9|P72524
- Organism
- Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
- Action type
- Inhibitor
- Gene symbol
- parC|parE
- Protein identifier
- P72525|Q59961
- Organism
- Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
- Condition
- Prostatic Hyperplasia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000284
- Subject identifier
- D011470
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Skin Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Cellulitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003035
- Subject identifier
- D002481
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Prostatitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003830
- Subject identifier
- D011472
- Condition
- Otitis Media
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004992
- Subject identifier
- D010033
- Condition
- Staphylococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005681
- Subject identifier
- D013203
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Bronchitis, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006505
- Subject identifier
- D029481
- Condition
- Appendicitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007149
- Subject identifier
- D001064
- Condition
- Influenza, Human
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Maxillary Sinusitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007361
- Subject identifier
- D015523
- Condition
- Tuberculosis, Multidrug-Resistant
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007381
- Subject identifier
- D018088
- Condition
- Sinusitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Dyspepsia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008533
- Subject identifier
- D004415
- Condition
- Bronchitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009661
- Subject identifier
- D001991
- Condition
- Tuberculosis, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000049
- Subject identifier
- D014397
- Condition
- Conjunctivitis, Bacterial
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000829
- Subject identifier
- D003234
- Condition
- Helicobacter Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
And 18 more, listed on the interactive page.
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000684
- Condition identifier
- EFO_0000701
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0000778
- Condition identifier
- EFO_0003035
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0003830
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004992
- Condition identifier
- EFO_0005046
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005224
- Condition identifier
- EFO_0006505
- Condition identifier
- EFO_0006789
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007149
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007185
- Condition identifier
- EFO_0007315
- Condition identifier
- EFO_0007361
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007420
- Condition identifier
- EFO_0007486
And 96 more, listed on the interactive page.
- Event
- creatinine renal clearance decreased
- Reports
- 173
- Reporting signal score
- 352.46
- Event
- drug hypersensitivity
- Reports
- 2,493
- Reporting signal score
- 2,910.07
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 382
- Reporting signal score
- 443.925
- Event
- electrocardiogram qt prolonged
- Reports
- 339
- Reporting signal score
- 278.615
- Event
- pathogen resistance
- Reports
- 247
- Reporting signal score
- 463.7
- Event
- rotator cuff syndrome
- Reports
- 328
- Reporting signal score
- 746.609
- Event
- sedation complication
- Reports
- 173
- Reporting signal score
- 508.135
- Event
- tendon disorder
- Reports
- 426
- Reporting signal score
- 1,301.44
- Event
- tendon pain
- Reports
- 444
- Reporting signal score
- 1,422.75
- Event
- tendon rupture
- Reports
- 1,041
- Reporting signal score
- 3,358.12
- Event
- tendonitis
- Reports
- 925
- Reporting signal score
- 2,778.51
- NCT00000778
- NCT00001033
- NCT00396084
- NCT01055145
- NCT01918397
- NCT02409290
- NCT02619994
- NCT02975570
- NCT03474198
- NCT03828201
- NCT00002249
- NCT00005590
- NCT00020865
- NCT00081575
- NCT00245791
- NCT00906048
- NCT01109823
- NCT05575427
- NCT06172010
- NCT00034736
- NCT00035347
- NCT00236821
- NCT00236834
- NCT00253955
- NCT00257049
And 85 more, listed on the interactive page.
- Dose
- 250mg, 500mg, or 750mg
- Route
- Oral
- How often
- Every 24 hours
- Administer without regard to food
- Maintain adequate hydration
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 75.01
- Calculated partition coefficient (ALogP)
- 1.54
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 53
- Molecular formula
- C36H42F2N6O9
- Monoisotopic mass
- 740.29813326
- Natural product
- No
- 0143-9315
- 0143-9316
- 0143-9317
- 0143-9720
- 0143-9721
- 0143-9722
- 0409-2220
- 0409-3330
- 0409-4444
- 0527-1948
- 0904-6351
- 0904-6352
- 0904-6353
- 25021-132
- 31722-721
- 31722-722
- 31722-723
- 33342-531
- 33342-532
- 33342-533
- 36000-045
- 43063-457
- 43063-459
- 44567-435
- 44567-436
And 96 more, listed on the interactive page.
- Recorded assays
- 8,021
- Active assays
- 124
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- -0.43
- Mean
- -1.01
- Minimum
- -2.19
- Maximum
- -0.41
- Unit
- unitless
- Assays
- 3
- Standard deviation
- 1.02196
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 99
- Mean
- 98.5
- Minimum
- 97.5
- Maximum
- 99
- Unit
- %
- Assays
- 3
- Standard deviation
- 0.866025
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 32.2
- Mean
- 32.2
- Minimum
- 32.2
- Maximum
- 32.2
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (260)
- "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
- "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province
- A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.
- A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.
- A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection
- A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control
- A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control
- A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis
- A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients
- A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults
- A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
- A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
- A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis
- A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days.
- A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Approved for (23)
- Anthrax infection
- Bacterial conjunctivitis
- Bacterial infectious disease
- Blepharitis
- Brucellosis
- Chronic bronchitis
- Conjunctivitis
- Corneal ulcer
- Cystic fibrosis
- Eye infectious disorder
- Hordeolum
- Keratitis
- Otitis externa
- Paratyphoid fever
- Plague
- Pneumonia
- Q fever
- Respiratory system disorder
- Respiratory tract infectious disorder
- Sinusitis
In development for (42)
- Acute maxillary sinusitis Phase 3
- Acute pyelonephritis Phase 3
- Appendicitis Phase 2
- Asthma Phase 2
- Bacterial pneumonia Phase 3
- Benign prostatic hyperplasia Phase 3
- Bronchitis Phase 3
- Cancer Phase 2
- Cataract Phase 3
- Cellulitis Phase 2
- Chronic obstructive pulmonary disease Phase 3
- Chronic prostatitis Phase 3
- Chronic rhinosinusitis Phase 1
- COVID-19 Phase 3
- Cutaneous leishmaniasis Phase 2
- Diarrheal disease Phase 1
- Dyspepsia Phase 3
- Endophthalmitis Phase 1
- Escherichia coli infection Phase 1
- Helicobacter pylori infectious disease Phase 3
Other linked conditions (13)
- Autoimmune thrombocytopenic purpura
- Chronic endometritis
- Chronic gastritis
- Constipation disorder
- Delirium
- Drug-resistant tuberculosis
- Empyema
- Fungal keratitis
- Gastric cancer
- Gastritis
- Ischemic stroke
- Mycobacterium avium complex disease
- Peptic ulcer disease